The goal of this observational pilot study is to evaluate the investigational AK+ Guard™ software as a medical device (SaMD) for detection of moderate to severe hyperkalemia (serum potassium (K+) ≥ 6.5 mmol/L) in adults with chronic kidney disease (CKD). Study objectives are: * Arm 2A (Outpatient Diagnostic Accuracy): To generate a preliminary, real-world signal of the diagnostic performance of AK+ Guard™ when used in an ambulatory CKD cohort for identifying clinically significant hyperkalemia episodes (serum K+ ≥ 6.5 mmol/L) at the time of an outpatient laboratory draw. * Arm 2B (Remote Patient Monitoring): To assess participant compliance, usability, and end-to-end system reliability of AK+ Guard™ when deployed for daily remote monitoring of CKD patients outside the clinical environment for up to four weeks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Arm 2A: Sensitivity and specificity of AK+ Guardâ„¢ for detecting serum potassium greater than or equal to 6.5 mmol/L
Timeframe: Baseline (Day 0)
Arm 2B: (a) Daily compliance rate (proportion of completed ECGs out of scheduled ECGs)
Timeframe: Daily monitoring up to 4 weeks (Day 28)
Arm 2B: (b) Mean System Usability Scale (SUS) score
Timeframe: Study completion at Week 4 (Day 28)
Arm 2B: (c) Net Promoter Score (NPS)
Timeframe: Study completion at Week 4 (Day 28)